alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2021028EN.01000601.xml

| 25.1.2021 | EN | Official Journal of the European Union | C 28/6 |
| --- | --- | --- | --- |

25.1.2021

EN

Official Journal of the European Union

C 28/6

---

Judgment of the Court (Ninth Chamber) of 18 November 2020 (request for a preliminary ruling from the Tribunale ordinario di Torino — Italy) — Techbau SpA v Azienda Sanitaria Locale AL

(Case C-299/19) (1)

(Reference for a preliminary ruling - Combating late payments in commercial transactions - Directive 2000/35/EC - Concept of ‘commercial transactions’ - Concepts of ‘delivery of goods’ and ‘provision of services’ - Article 1 and first subparagraph of Article 2(1) - Public works contract)

(2021/C 28/07)

Language of the case: Italian

Referring court

Tribunale ordinario di Torino

Parties to the main proceedings

Applicant: Techbau SpA

Defendant: Azienda Sanitaria Locale AL

Operative part of the judgment

The first subparagraph of Article 2(1) of Directive 2000/35/EC of the European Parliament and of the Council of 29 June 2000 on combating late payment in commercial transactions must be interpreted as meaning that a public works contract constitutes a commercial transaction which leads to the delivery of goods or the provision of services within the meaning of that provision and, therefore, falls within the material scope of that directive.

---

(1)  OJ C 213, 24.6.2019.

---
# C_2019255EN.01003702.xml

| 29.7.2019 | EN | Official Journal of the European Union | C 255/37 |
| --- | --- | --- | --- |

29.7.2019

EN

Official Journal of the European Union

C 255/37

---

Judgment of the General Court of 6 June 2019 — Porsche v EUIPO — Autec (Motor vehicles)

(Case T-209/18) (1)

(Community design - Invalidity proceedings - Registered Community design representing a motor vehicle - Earlier Community design - Ground for invalidity - No individual character - Article 6 and Article 25(1)(b) of Regulation (EC) No 6/2002)

(2019/C 255/48)

Language of the case: German

Parties

Applicant: Dr. Ing. h.c. F. Porsche AG (Stuttgart, Germany) (represented by: C. Klawitter, lawyer)

Defendant: European Union Intellectual Property Office (represented by: S. Hanne, acting as Agent)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Autec AG (Nuremberg, Germany) (represented by: M. Krogmann, lawyer)

Re:

Action brought against the decision of the Third Board of Appeal of EUIPO of 19 January 2018 (Case R 945/2016-3), relating to invalidity proceedings between Autec AG and Dr. Ing. h.c. F. Porsche AG.

Operative part of the judgment

The Court:

| 1) | Dismisses the action; |
| --- | --- |

1)

Dismisses the action;

| 2) | Orders Dr. Ing. h.c. F. Porsche AG to pay the costs. |
| --- | --- |

2)

Orders Dr. Ing. h.c. F. Porsche AG to pay the costs.

---

(1)  OJ C 166, 14.5.2018.

---
#### Robert Cleo PATTERSON, III, Appellant, v. UNITED STATES of America, Appellee.

No. 20255.

United States Court of Appeals Fifth Circuit.

Nov. 6, 1963.

*311Robert Cleo Patterson, III, pro se.

Vemol R. Jansen, Jr., U. S. Atty., Mobile, Ala., William A. Kimbrough, Jr., Asst. U. S. Atty., S. D. of Alabama, for appellee.

Before RIVES, WISDOM and GEWIN, Circuit Judges.

PER CURIAM.

Appellant was convicted on a two-count information, the first charging a violation of 18 U.S.C.A. § 2312 in that defendant transported in interstate commerce a stolen automobile knowing the vehicle to have been stolen, and the second charging a violation of 18 U.S.C.A. § 2314 in that the defendant did unlawfully and knowingly and with fraudulent intent cause to be transported in interstate commerce a forged security, to-wit, a $50.00 check, knowing the security to have been forged. The defendant pleaded guilty to each charge and was sentenced to a period of five (5) years in the custody of the Attorney General.

On this Section 2255 (of Title 28 United States Code) motion, the appellant claims that the two charges have nothing to do with each other and are thus duplicitous and prejudicial. We think the two counts charged violations of “the same or similar character.” Rule 8(a), Fed.R.Crim.P. Edwards v. Squier, 9 Cir. 1949, 178 F.2d 758. Further, any impropriety in the two counts would be harmless because of defendant’s plea of guilty and the concurrence of the sentences.

In his pro se brief, appellant further contends that the automobile which he transported was not stolen when he transported it, but was leased. There is no merit in this contention. See Miller v. United States, 4 Cir. 1958, 261 F.2d 546; Brown v. United States, 8 Cir. 1960, 277 F.2d 201.

The judgment is

Affirmed.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                      15,267,000
<SECURITIES>                                         0
<RECEIVABLES>                              294,928,000
<ALLOWANCES>                                10,850,000
<INVENTORY>                                          0
<CURRENT-ASSETS>                           346,859,000
<PP&E>                                      43,996,000
<DEPRECIATION>                              57,441,000
<TOTAL-ASSETS>                             429,053,000
<CURRENT-LIABILITIES>                      344,570,000
<BONDS>                                    137,488,000<F1>
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       242,000
<OTHER-SE>                                  63,360,000
<TOTAL-LIABILITY-AND-EQUITY>               429,053,000
<SALES>                                              0
<TOTAL-REVENUES>                             1,216,466<F2>
<CGS>                                                0
<TOTAL-COSTS>                                1,077,356
<OTHER-EXPENSES>                               141,261
<LOSS-PROVISION>                            76,210,000
<INTEREST-EXPENSE>                          20,279,000
<INCOME-PRETAX>                            (97,101,000)
<INCOME-TAX>                               (11,357,000)
<INCOME-CONTINUING>                        (85,744,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                             (1,090,000)
<CHANGES>                                   (6,000,000)
<NET-INCOME>                              (100,532,000)
<EPS-PRIMARY>                                    (4.17)
<EPS-DILUTED>                                    (4.17)
<FN>
<F1>Excludes current portion of bonds, mortgages, and similar debt.
<F2>Represents gross revenue which includes costs of certain services
subcontract3d to third parties and other reimbursable direct project costs,
such as materials procured by the company on behalf of its customers. Gross
revenue also includes equity income in affiliates for purpose of this schedule.
</FN>
        

</TABLE>
CSB BANCORP, INC.EXHIBIT 11STATEMENT REGARDING COMPUTATION OF PER SHARE EARNINGS                   Three Months Ended  Six Months Ended   June 30,  June 30,   2006  2005  2006  2005 **Basic Earnings Per Share**                Net income $676,653  $613,744  $1,450,559  $1,280,557                  Weighted averagecommon shares  2,531,456   2,644,968   2,551,661   2,644,966 **Basic EarningsPer Share** $0.27  $0.23  $0.57  $0.48                               **Diluted Earnings Per Share**                Net income $676,653  $613,744  $1,450,559  $1,280,557 Weighted averagecommon shares  2,531,456   2,644,968   2,551,661   2,644,966 Weighted average effect ofassumed stock options  3,565   3,318   3,788   3,199                               Total  2,535,021   2,648,286   2,555,449   2,648,165                               **Diluted EarningsPer Share** $0.27  $0.23  $0.57  $0.48
# C_2021035EN.01001302.xml

| 1.2.2021 | EN | Official Journal of the European Union | C 35/13 |
| --- | --- | --- | --- |

1.2.2021

EN

Official Journal of the European Union

C 35/13

---

Judgment of the Court (First Chamber) of 3 December 2020 — Région de Bruxelles-Capitale v European Commission

(Case C-352/19 P) (1)

(Appeal - Regulation (EC) No 1107/2009 - Placing of plant protection products on the market - Implementing Regulation (EU) 2017/2324 - Renewal of the approval of the active substance glyphosate - Article 263 TFEU - Standing to bring proceedings of a regional body - Whether directly concerned)

(2021/C 35/17)

Language of the case: French

Parties

Appellant: Région de Bruxelles-Capitale (represented by: A. Bailleux, avocat)

Other party to the proceedings: European Commission (represented by: X. Lewis, F. Castillo de la Torre, I. Naglis and F. Castilla Contreras, acting as Agents)

Operative part of the judgment

The Court:

| 1. | Dismisses the appeal; |
| --- | --- |

1.

Dismisses the appeal;

| 2. | Orders the Région de Bruxelles-Capitale to pay the costs. |
| --- | --- |

2.

Orders the Région de Bruxelles-Capitale to pay the costs.

---

(1)  OJ C 220, 1.7.2019.

---
SAT Report

PMN Number: P-14-0202

SAT Date: 1/10/2014

Print Date: 6/4/2014

Related cases:

Concern levels:

Type of Concern: Health Eco Comments

Level of Concern: 2 3

 Persistence Bioaccum Toxicity Comments

1 21

Exposure Based Review:

Health: No

Ecotox: Yes

Routes of exposure: Health: Dermal Inhalation 

Ecotox: All releases to water

Fate: ;

Keywords:

 Keywords: IRR/CORR-S,E,L,MM; AQUATOX

Summary of Assessment:

 Fate:

Fate Summary: P-14-0202-06

FATE: Estimations for typical low weight 

log Kow = 7.72 (E) 

S = 0.005 mg/L at 25 C (E)

BP > 400 C (E)

H = 1.79E-8 (E)

log Koc = 6.20 (E)

log Fish BCF = 3.17 (E)

EPA SANITIZED Page 1 of 2
log Fish BAF = 5.07 (E) 

POTW removal (%) = 90 via sorption

Time for complete ultimate aerobic biodeg = wk-mo

Sorption to soils/sediments = v.strong

PBT Potential: P1B2

*CEB FATE: Migration to ground water = negl

 Health:

 Health Summary: Absorption is poor from the skin, moderate from the GI 

tract, and good from the lung (analog). Concern for severe irritation and possible corrosion from 

the 

 Ecotox:

Test Organism Test 

Type

Test End 

Point

Predicted Measured Comments

fish 96-h LC50 *

daphnid 48-h LC50 *

green algal 96-h EC50 *

fish _ chronic value 0.001

daphnid _ chronic 

value

0.001

algal _ chronic 

value

0.001

Sewage Sludge 3-h EC50 _

Sewage Sludge _ Chronic 

Value

_

Ecotox Values Comments: Predictions are based on SARs for ; SAR 

chemical class = MW 324; log Kow 6.7 (EPI); with unknown 

mp (P); S = 0.052 mg/L (P); effective concentrations based on 100% active ingredients and 

mean measured concentrations; hardness <150.0 mg/L as CaCO3; and TOC <2.0 mg/L;

Factors Values Comments

Assessment Factor 10

Concentration of Concern 

(ppb)

1

SARs

SAR Class

Ecotox Category 

Ecotox Factors Comments: 

 SAT Chair: L Keifer 564-8916

EPA SANITIZED Page 2 of 2
Exhibit 99.2



VERTEL CORPORATION



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT 2002



In connection with the Quarterly Report of Vertel Corporation (the Company) on Form 10-Q for the period ending March 31, 2003 as filed with
the Securities and Exchange Commission on the date hereof (the Report), I, Marc E. Maassen, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the
Sarbanes-Oxley Act of 2002, that:



| | 1. |  | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | -- |  | ---------------------------------------------------------------------------------------------------------------------



| | 2. |  | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| | -- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------



|                                                                                                                    
|--------------------------------------------------------------------------------------------------------------------
|/s/    T. JAMES
RANNEYT.
James Ranney Vice President Finance & Administration, Chief Financial Officer and Secretary
|



May 20, 2003



A signed original
of this written statement required by Section 906 has been provided to Vertel Corporation and will be retained by Vertel Corporation and furnished to the Securities and Exchange Commission or its staff upon request.



30
**From:** Brachtl, Megan

**Sent:** Thursday, July 23, 2015 12:54 PM **To:** 'Szabo, Aaron'; Ling, Michael **Subject:** RE: SO2 Data Requirements Rule: RLSO and Clean Version **Importance:** High Aaron – Attached please find the documents you requested. Please let me know if you have any questions. Thanks, Megan Megan V. Brachtl, Group Leader State and Local Programs Group Office of Air Quality Planning and Standards U.S. Environmental Protection Agency (919) 541
- 2648 brachtl.m egan@epa.gov **From:** Szabo, Aaron [ mailto:Aaron_L_Szabo@omb.eop.gov] **Sent:** Wednesday, July 22, 2015 6:09 PM **To:** Ling, Michael; Brachtl, Megan **Subject:** SO2 Data Requirements Rule: RLSO and Clean Version Mike and Megan, When you are available, can you send me a final clean and redline
- strikeout version (from the original version sent to OMB) of the SO2 Data Requirements rule? Thanks. Aaron L. Szabo Policy Analyst Office of Management and Budget 202
- 395
-3621 Aaron_L_Szabo@omb.eop.gov
##### 



EXHIBIT 32.1 Section 906 Certification of Chief Executive Officer

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT OT
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of SBS Technologies, Inc. (the
Company) on Form 10-Q for the fiscal quarter ended September 30, 2003, as
filed with the Securities and Exchange Commission on the date hereof, (the
Report), I, Clarence W. Peckham, Chief Executive Officer of the Company,
certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the
Sarbanes-Oxley Act of 2002, that:



| | (1) |  | The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934; and
| | --- |  | ---------------------------------------------------------------------------------------------------------------------



| | (2) |  | The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of
the Company.
| | --- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------

/s/ Clarence W. Peckham

Clarence W. Peckham
Chief Executive Officer
November 12, 2003
Federal Relay Service

 APHIS is an agency of USDA’s Marketing and Regulatory Programs (Voice/TTY/ASCII/Spanish)

An Equal Opportunity Provider and Employer 1-800-877-8339

Safeguarding American Agriculture

November 3, 2008 

CENTER FOR VETERINARY BIOLOGICS NOTICE NO. 08-18

TO: VS Management Team 

Directors, Center for Veterinary Biologics 

Biologics Licensees, Permittees, and Applicants 

FROM: Richard E. Hill, Jr. /s/ Byron E. Rippke for 

Director 

Center for Veterinary Biologics 

SUBJECT: Changes to the Administrative Inspection Review Program 

I. PURPOSE

The purpose of this notice is to inform interested parties of the changes to the Center for 

Veterinary Biologics (CVB) Administrative Inspection Review (AIR) program. 

II. BACKGROUND

The CVB requests information from licensed firms for the AIR program in accordance 

with Title 9 CFR Part 116.5(a). Since the inception of the AIR program in 2005, the 

CVB has received a large volume of submissions from firms. Most of the information 

the CVB has requested has been repetitive from year to year. In an attempt to simplify 

the process and alleviate the amount of information required from the firms, the CVB has 

made modifications to the AIR process. 

III. GUIDANCE

The AIR will continue to be sent to all licensees each fiscal year (FY); however, effective 

October 1, 2008 (FY 09), the CVB will initiate a 3-year rotation for the AIR process, as 

follows: 

First year, FY 09 – condensed version of the AIR Form 

Second year, FY 10 – condensed version of the AIR Form 

Third year, FY 11 – full version of the AIR form 

EXCEPTIONS: 

1) The permittees will continue to receive the full-length version in FY 09, with the

condensed version provided the following 2 years (FY 10 and 11)

2) All newly licensed and permitted firms will begin with the full version of the AIR

form. 

United States 

Department of 

Agriculture

Animal and Plant 

Health Inspection 

Service 

Veterinary Services 

Center for Veterinary 

Biologics 

510 S. 17th Street, 

Suite 104 

Ames, IA 50010 

(515) 232-5785

FAX (515) 232-7120

ARCHIVED
CENTER FOR VETERINARY BIOLOGICS NOTICE NO. 08-18 

Page 2 

The AIR form will consist of two sections for both versions described above; however, 

the condensed AIR form will request only a few key items. Attached is a copy of the 

new AIR form for FY 09, subject to change. 

Please note the CVB will also be including a new focus question to the AIR form each 

fiscal year. For FY 09, information concerning expiration date determination (Title 9 

CFR Part 114.13) will be required. The CVB will be reviewing each firm’s expiration 

date confirmation for all products. This request may include the following: 

• list of all licensed products 

• date the stability study was completed 

• date the final report was submitted to the CVB 

• date the CVB responded to the report 

A screen fillable AIR form, for licensed firms, will be posted on the CVB website located 

at: http://www.aphis.usda.gov/animal_health/vet_biologics/vb_forms.shtml. 

Attachment 

ARCHIVED
<PAGE>   1

                        SCIENTIFIC GAMES HOLDINGS CORP.               EXHIBIT 11
                       COMPUTATION OF PER SHARE EARNINGS
                      (IN THOUSANDS EXCEPT PER SHARE DATA)



<TABLE>
<CAPTION>
                                                                                         Three-month period
                                                                                           ended March 31,
                                                                                        1997           1996  
                                                                                      -------        --------
<S>                                                                                   <C>             <C>
Net earnings ....................................................                     $ 5,487         $ 1,511

Weighted average Common stock outstanding........................                      12,162          13,065

Effect of common stock equivalents (stock
  options), at average market price..............................                         434             676                
                                                                                      -------         -------              

         Total...................................................                      12,596          13,741
                                                                                      =======         =======

Net earnings per common share....................................                     $   .44         $   .11
                                                                                      =======         =======
</TABLE>
% Food exposure

% Once daily oral exposure, dose from cpfs SS F13_49 foodonly exp distribution.csv 50th percentile

% Female adult, Body weight set to 72.9 kg

% Cecilia Tan

% August 26, 2015

prepare @clear @all

% Setting model parameters

start @NoCallback

use human_parameters_MRP

use preg_female_parameters

BWSW=1;% Set to 1 if BWT is provided

BWST=72.9;% Initial BW in kg

PREG=0;% not pregnant

TSTOP= 1008; % Exposure duration in hrs

%Single daily oral exposure

DT = xlsRead("Food.xls", "50p", "A1:A43"); % Dosing Times

DORAL=xlsRead("Food.xls", "50p", "B1:B43"); % Dose in ug/kg

prepare time rbcce cv urinetcpy

start@nocallback

mytable = [_time _rbcce _urinetcpy _cv*350.6];%unit of conc = ug/L

save mytable @file='food_50.txt' @format=ascii
**EXHIBIT
32.2**
 
 CERTIFICATION
PURSUANT TO
 18 U.S.C.
SECTION 1350,
 AS
ADOPTED PURSUANT TO
 SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
 
 
 In
connection with the Quarterly Report of MISONIX, INC. (the “Company”) on Form
10-Q for the period ending March 31, 2005 as filed with the Securities and
Exchange Commission on the date hereof (the “Report”), I, Richard Zaremba,
Senior Vice President, Chief Financial Officer, Treasurer and Secretary of the
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that:
 
 (1)
    The
      Report fully complies with the requirements of section 13(a) or 15(d) of
      the Securities Exchange Act of 1934; and
 
 (2)
    The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and result of operations of the
      Company.
  Date: May 13, 2005
    By:
    /s/ Richard
  ZarembaRichard Zaremba
      Senior Vice President, Chief Financial
      Officer
      Treasurer and Secretary
 A signed
original of this written statement required by Section 906, or other document
authenticating, acknowledging, or otherwise adopting the signature that appears
in typed form within the electronic version of this written statement required
by Section 906, has been provided to MISONIX, INC. and will be retained by
MISONIX, INC. and furnished to the Securities and Exchange Commission or its
staff upon request.
 
  -31-